Systemic Treatment of Soft Tissue Sarcomas in the Geriatric Population

Curr Treat Options Oncol. 2022 Jun;23(6):855-863. doi: 10.1007/s11864-022-00972-2. Epub 2022 Apr 7.


As the population ages, there will be an increase in the incidence and prevalence of soft tissue sarcoma (STS) within the geriatric population. As this disease disproportionately affects older adults, the percentage of adults >65 years old is expected to increase in the coming years. Geriatric patients are often more vulnerable to disease-related symptoms and have more difficulty tolerating treatment-related side effects. While there are no formal existing guidelines to direct the care of this geriatric patient population, it is of utmost importance to consider each patients' fitness and co-morbidities when selecting treatment plans. This review focuses on the current state of research of older adults with advanced or metastatic soft tissue sarcoma, highlighting the lack of representation of this patient population in clinical trials. Given that chronological age does not necessarily equate to physiologic age, integration of comprehensive geriatric and quality of life assessments is needed in the care of geriatric patients to help guide therapeutic decisions.

Keywords: Chemotherapy; Geriatrics; Patient-reported outcomes; Quality of life; Soft tissue sarcoma.

Publication types

  • Review

MeSH terms

  • Aged
  • Comorbidity
  • Geriatric Assessment
  • Humans
  • Quality of Life
  • Sarcoma* / drug therapy
  • Sarcoma* / epidemiology
  • Soft Tissue Neoplasms*